Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells

Ewelina Szliszka1, Dagmara Jaworska, Małgorzata Ksek

  • 1Chair and Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Jordana 19, 41-808 Zabrze, Poland. wkrol@sum.edu.pl.

Insights

Chalcones can enhance cancer cell sensitivity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) therapy. This study shows chalcones increase TRAIL-R2 expression, overcoming TRAIL resistance and augmenting antitumor activity.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell apoptosis.
  • Cancer cells can develop resistance to TRAIL-mediated apoptosis.
  • Chalcones are investigated for their potential to overcome this resistance.

Purpose of the Study:

  • To evaluate the combined cytotoxic and apoptotic effects of TRAIL with four chalcones on HeLa cancer cells.
  • To investigate the role of chalcones in modulating TRAIL death receptor expression.
  • To confirm the cancer chemopreventive properties of chalcones.

Main Methods:

  • Cytotoxicity assessed using MTT and LDH assays.
  • Apoptosis detected via annexin V-FITC staining (flow cytometry and fluorescence microscopy).
  • Death receptor expression analyzed by flow cytometry.

Main Results:

  • Chalcones sensitized HeLa cancer cells to TRAIL-induced apoptosis.
  • Chalcones increased the expression of TRAIL-R2 (death receptor).
  • This suggests chalcones can overcome TRAIL resistance by upregulating death receptors.

Conclusions:

  • Chalcones augment the antitumor activity of TRAIL.
  • Chalcones demonstrate cancer chemopreventive properties by enhancing TRAIL-mediated apoptosis.
  • Targeting TRAIL-R2 expression with chalcones is a potential strategy against TRAIL-resistant cancers.